Poxel releases detailed Imeglimin Phase 3 results from TIMES 1 program
Category: #health  By Pankaj Singh  Date: 2019-09-20
  • share
  • Twitter
  • Facebook
  • LinkedIn

Poxel releases detailed Imeglimin Phase 3 results from TIMES 1 program

Type 2 diabetes is a prevailing disease in which cells become unresponsive to insulin while gradually increasing blood sugar. With growing cases of Type 2 diabetes worldwide, pharmaceutical companies are now focusing on developing new drugs by means of novel clinical trials.

POXEL S.A., a biopharmaceutical company focused on developing novel treatments and drugs for metabolic disorders like non-alcoholic steatohepatitis (NASH) and type 2 diabetes, recently presented a detailed Phase 3 results from the TIMES (Trials of Imeglimin for Efficacy and Safety) 1 program.

According to reports, the data would be displayed in a symposium session at the 55th Annual Meeting of EASD (European Association for the Study of Diabetes), conducted in Barcelona, Spain.

Speaking on the move, Ralph DeFronzo, M.D., Professor of Medicine and Chief of the Diabetes Division at UT Health San Antonio, said that to effectively administer type 2 diabetes, treatments need to fix both the defects in insulin sensitivity and insulin secretion.

He added that Poxel’s new treatment is an innovative therapeutic approach with an exclusive mechanism of action that operates on the level of the mitochondria. Moreover, by advancing mitochondrial function, the drug has shown a rise in insulin secretion and muscle insulin sensitivity while decreasing hepatic glucose production.

Previously, the company had partnered with Sumitomo Dainippon Pharma Co., Ltd, to announce encouraging top-line Phase 3 results for Imeglimin TIMES 3 16-week, placebo-controlled, randomized, double-blind clinical trial aimed to treat type 2 diabetes in Japan.

Reportedly, the Phase 3 study in Japan involved three crucial trials to assess Imeglimin’s safety and efficacy across 1,100 patients.

According to Prof. Hirotaka Watada, MD, PhD, Professor at Department of Metabolism & Endocrinology, Juntendo University, Tokyo, Imeglimin’s unique mechanism of action that focuses on very significant deficiencies occurring in diabetes combined with its safety profile, could massively improve the health of Japanese patients who earlier relied on insulin.

Source Credit: https://www.poxelpharma.com/en_us/news-media/press-releases/detail/128/poxel-announces-detailed-imeglimin-phase-3-times-1-results



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Anova Enterprises expands AnovaOS™ to boost clinical development
Anova Enterprises expands AnovaOS™ to boost clinical development
By Pankaj Singh

The U.S-based Anova Enterprises, Inc. (Anova) has reportedly expanded the AnovaOS™ technology platform in order to boost the development of promising novel treatments. The platform brings pharmaceutical companies...

Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
By Pankaj Singh

India’s Drugs Controller General (DCGI) has approved Pune-based Serum Institute of India (SII) to restart the clinical trial of the Oxford/AstraZeneca COVID-19 vaccine in India.

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results
By Pankaj Singh

Everest Medicines announced the top-line results from the Phase 1 clinical trial of Taniborbactam with cefepime for treating infections caused by multi-drug resistant pathogens in China. Everest Medicines is a biopharm...